Physician profile
Scott J Walker
NPI 1801085618
$8,302.19
in general payments reported to CMS, 2019-2025
48 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,015 · 2020: $1,274 · 2021: $416 · 2022: $666 · 2023: $483 · 2024: $1,290 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.56 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,406.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $804.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $773.49 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Pfizer INC. | $698.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $685.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $423.50 | 2020-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.76 | 2019-2025 | Jardiance, Ofev |
| Allergan, INC. | $268.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.16 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $229.57 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $177.77 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $159.87 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $150.32 | 2019-2020 | |
| Amgen INC. | $145.95 | 2020-2025 | Otezla, Repatha, Repatha |
| Genentech, INC. | $135.10 | 2023 | Susvimo, Vabysmo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.